Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 in Relapsing-Remitting Multiple Sclerosis
NCT02038049Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2013
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ianalumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Started Dec 2013; status: terminated.
02
Drugs
ianalumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02038049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038049.